DDInter1042 DDInter1796
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Thioridazine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Thioridazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Thioridazine {u} (Compound) binds {v} (Gene) CYP2D6
Thioridazine {u} (Compound) upregulates {v} (Gene) KDM5B
Thioridazine {u} (Compound) palliates {v} (Disease) schizophrenia
Thioridazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Thioridazine {u} (Compound) downregulates {v} (Gene) VAPB
Thioridazine {u} (Compound) causes {v} (Side Effect) Cholestasis
Thioridazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Thioridazine (Compound) resembles Prochlorperazine (Compound)
Thioridazine (Compound) resembles Ethopropazine (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Thioridazine (Compound) binds CYP2D6 (Gene)
Thioridazine (Compound) upregulates KDM5B (Gene)
Thioridazine (Compound) palliates schizophrenia (Disease)
Thioridazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Thioridazine (Compound) downregulates VAPB (Gene)
Thioridazine (Compound) causes Cholestasis (Side Effect)
Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide